Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,492.00
Ask: 12,496.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,526.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-No U.S. rate rise until 2024?

Fri, 30th Apr 2021 10:07

* Europe's STOXX 600 up 0.1%

* Basic materials index worst performer, down 1%

* Barclays tumbles after cautious guidance

* Healthcare stock index leads gains up 0.8%

April 30 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

NO U.S. RATE RISE UNTIL 2024? (0905 GMT)

A Fed tapering might be dangerous for equities, but we
should also ask ourselves if investors have already priced that
in.

UBS analysts have a pretty clear idea on the matter. They
expect “discussions on bond purchase tapering (by the Fed) to
surface in the second half of the year.”

But they “believe markets have largely priced in this
expectation.” In addition, they “do not expect any rate hike
until 2024.”

This would mean that equities will benefit from the
ultra-loose policy by the U.S. government, without worrying
about yields for a reasonable length of time.

But there are still reasons to expect more market turbulence
“as investors fret over rising inflation and the uneven global
progress in combating the pandemic,” UBS analysts say.

Bottom line, equities can rise further, but better to be
exposed to the “cyclical part of the market such as financials,
energy and value stocks.”

The chart shows the 10-year U.S. bond yields and the U.S.
dollar forward inflation-linked swap.

(Stefano Rebaudo)

*****

EARNINGS PROP UP STOXX, BUT BANKS UNDER PRESSURE (0745 GMT)

European stocks opened slightly higher as a batch of solid
company results boosted risk sentiment and offset worries about
rising bond yields.

The STOXX 600 index is up 0.2% with autos,
construction and materials stocks leading gains. Banks
are on the negative side, down 0.7% after yesterday’s
rise.

Barclays shares are down 5.5% after results.

Shares in AstraZeneca are rising 2.7% after the
company reports Q1 profit and sales ahead of expectations and
forecast higher sales in Q2.

Swiss Re stocks are up 4% after the company swang
to Q1 net profit, which was better than analysts expectations.

Investors will focus on today’s eurozone inflation figures
which might add more fuel to the fire of worries about rising
yields. Some analysts see upside risks, while most see a modest
decline in core numbers.

Eyes also on the U.S. core PCE Price Index with analysts
expecting a sizable jump.

(Stefano Rebaudo)

*****

EUROPE MAY OFFER STEER FOR WEEKEND CHEER (0658 GMT)

It's Europe's turn to confirm an improving global outlook,
a day after strong U.S. data and upbeat earnings lifted the S&P
500 to a record high close.

So far, so good: BNP Paribas, the euro zone's biggest listed
lender, posted a better-than-expected first-quarter profit while
Q1 profit at British bank Barclays more than doubled.

Next up is GDP data. Ahead of a euro-wide number released
later this morning, France revealed its economy grew a
stronger-than-expected 0.4% in Q1, having shrunk 1.4% in the
final quarter of 2020.

The euro zone economy is forecast to have shrunk 2% in the
first quarter year-on-year, versus a 4.9% fall in the final
quarter of last year.

A flash inflation estimate is also due; economists forecast
a 1.6% rise in the headline number in April versus a 1.3%
increase in March.

These figures may seem underwhelming compared to the United
States, which grew at a 6.4% annualized rate last quarter. Yet
sentiment appears to have turned a corner thanks to a pick-up in
the COVID vaccination rollout and signs economic activity has
held up relatively well in the face of ongoing restrictions.

That view perhaps is why Germany's 10-year Bund yield is
ending April almost 10 basis points higher -- even
as the U.S. equivalent is down 10 bps.

The recovery expectations, alongside upbeat earnings have
underpinned stocks, although Asian shares slipped on Friday and
European stock futures were a touch lower.

Copper, the other key growth barometer, also slipped after a
blistering rally to $10,000 a tonne, though it is on track for
the 12th monthly gain in the past 13 months.

Finally, the U.S. dollar skidded toward a fourth straight
weekly decline against a basket of peers, undermined by the
Federal Reserve's message of ultra-low rates for longer.

Key developments that should provide more direction to
markets on Friday:

- Earnings calendar: Exxon Mobil, Chevron, AbbVie, Charter
Communications, AstraZeneca.

-Nestle has bought the brands of vitamin and supplements
maker The Bountiful Company for $5.75 billion

-Darktrace lists in London but valuation well below reported
target

- U.S. March personal spending and income numbers due out.

- Credit Suisse board member Gottschling to exit after
Greensill, Archegos losses

- China official manufacturing PMI fell to 51.1 in April.

-British house prices posted the biggest single-month
increase since 2004

- Retailer Amazon posted record Q1 profits.

(Dhara Ranasinghe)

*****

EUROPE SUBDUED ON YIELDS RISE, CHINA WORRIES (0528 GMT)

European stock futures are slightly lower with no clear
trend emerging yet as a rise in yields is expected to put
pressure on some equity sectors while a mixed picture on Asian
markets dampens risk sentiment.

China stocks lost ground overnight after weak data on
concerns about a monetary policy tightening coupled with
Sino-U.S. tensions. U.S. President Joe Biden took aim at China
in his first speech to Congress, pledging to maintain a strong
U.S. military presence Indo-Pacific.

Biden's new spending plan and the dovish stance by the Fed
continue to support risk-appetite along with U.S. data released
yesterday, which showed American economic growth accelerated in
the first quarter.

(Stefano Rebaudo)

*****

More News
2 Apr 2024 09:54

LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
2 Apr 2024 09:09

LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine

(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
2 Apr 2024 07:08

US FDA gives green light for use of AstraZeneca's Voydeva

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.